Table 3. The main ocular adverse events and systemic adverse events reported.
| Event | Combination (n=245) |
Ranibizumab (n=266) |
||
| Number of reported case | Incidence (%) | Number of reported case | Incidence (%) | |
| Serious Ocular Adverse Events | ||||
| Endophthalmits | 1 | 0.41 | 2 | 0.75 |
| Macular hole | 1 | 0.41 | 0 | 0 |
| Other Ocular Adverse Events | ||||
| Eye pain | 27 | 11.02 | 21 | 7.89 |
| Conjunctival hemorrhage | 14 | 5.71 | 24 | 9.02 |
| Ocular hyperemia | 14 | 5.71 | 16 | 6.02 |
| Inraocular pressure increased | 8 | 3.27 | 7 | 2.63 |
| Reduced visual acuity | 17 | 6.94 | 14 | 5.26 |
| Blepharitis | 5 | 2.04 | 4 | 1.5 |
| Lacrimation increased | 4 | 1.63 | 9 | 3.38 |
| Myodesopsia | 2 | 0.82 | 8 | 3.01 |
| Photopsia | 1 | 0.41 | 5 | 1.88 |
| Maculopathy | 9 | 3.67 | 0 | 0 |
| Retinal hemorrhage | 10 | 4.08 | 6 | 2.26 |
| Retinal edema | 7 | 2.86 | 0 | 0 |
| Non-ocular Adverse Events | ||||
| Hypertension | 15 | 6.12 | 15 | 5.64 |
| Arterial thromboembolic | 6 | 2.45 | 8 | 3.01 |